Crotedumab has been used in trials studying the treatment of Diabetes Mellitus, Type 2.
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Diethylstilbestrol | Diethylstilbestrol may increase the thrombogenic activities of Crotedumab. |
| Chlorotrianisene | Chlorotrianisene may increase the thrombogenic activities of Crotedumab. |
| Conjugated estrogens | Conjugated estrogens may increase the thrombogenic activities of Crotedumab. |
| Estrone | Estrone may increase the thrombogenic activities of Crotedumab. |
| Estradiol | Estradiol may increase the thrombogenic activities of Crotedumab. |
| Dienestrol | Dienestrol may increase the thrombogenic activities of Crotedumab. |
| Ethinylestradiol | Ethinylestradiol may increase the thrombogenic activities of Crotedumab. |
| Mestranol | Mestranol may increase the thrombogenic activities of Crotedumab. |
| Estriol | Estriol may increase the thrombogenic activities of Crotedumab. |
| Estrone sulfate | Estrone sulfate may increase the thrombogenic activities of Crotedumab. |
| Quinestrol | Quinestrol may increase the thrombogenic activities of Crotedumab. |
| Hexestrol | Hexestrol may increase the thrombogenic activities of Crotedumab. |
| Tibolone | Tibolone may increase the thrombogenic activities of Crotedumab. |
| Synthetic Conjugated Estrogens, A | Synthetic Conjugated Estrogens, A may increase the thrombogenic activities of Crotedumab. |
| Synthetic Conjugated Estrogens, B | Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of Crotedumab. |
| Polyestradiol phosphate | Polyestradiol phosphate may increase the thrombogenic activities of Crotedumab. |
| Esterified estrogens | Esterified estrogens may increase the thrombogenic activities of Crotedumab. |
| Zeranol | Zeranol may increase the thrombogenic activities of Crotedumab. |
| Equol | Equol may increase the thrombogenic activities of Crotedumab. |
| Promestriene | Promestriene may increase the thrombogenic activities of Crotedumab. |
| Methallenestril | Methallenestril may increase the thrombogenic activities of Crotedumab. |
| Epimestrol | Epimestrol may increase the thrombogenic activities of Crotedumab. |
| Moxestrol | Moxestrol may increase the thrombogenic activities of Crotedumab. |
| Estradiol acetate | Estradiol acetate may increase the thrombogenic activities of Crotedumab. |
| Estradiol benzoate | Estradiol benzoate may increase the thrombogenic activities of Crotedumab. |
| Estradiol cypionate | Estradiol cypionate may increase the thrombogenic activities of Crotedumab. |
| Estradiol valerate | Estradiol valerate may increase the thrombogenic activities of Crotedumab. |
| Biochanin A | Biochanin A may increase the thrombogenic activities of Crotedumab. |
| Formononetin | Formononetin may increase the thrombogenic activities of Crotedumab. |
| Estetrol | Estetrol may increase the thrombogenic activities of Crotedumab. |
| Cetuximab | The risk or severity of adverse effects can be increased when Cetuximab is combined with Crotedumab. |
| Human immunoglobulin G | The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Crotedumab. |
| Omalizumab | The risk or severity of adverse effects can be increased when Omalizumab is combined with Crotedumab. |
| Adalimumab | The risk or severity of adverse effects can be increased when Adalimumab is combined with Crotedumab. |
| Abciximab | The risk or severity of adverse effects can be increased when Abciximab is combined with Crotedumab. |
| Gemtuzumab ozogamicin | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Crotedumab. |
| Indium In-111 satumomab pendetide | The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Crotedumab. |
| Infliximab | The risk or severity of adverse effects can be increased when Infliximab is combined with Crotedumab. |
| Trastuzumab | The risk or severity of adverse effects can be increased when Trastuzumab is combined with Crotedumab. |
| Rituximab | The risk or severity of adverse effects can be increased when Rituximab is combined with Crotedumab. |
| Basiliximab | The risk or severity of adverse effects can be increased when Basiliximab is combined with Crotedumab. |
| Muromonab | The risk or severity of adverse effects can be increased when Muromonab is combined with Crotedumab. |
| Digoxin Immune Fab (Ovine) | The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Crotedumab. |
| Ibritumomab tiuxetan | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Crotedumab. |
| Tositumomab | The risk or severity of adverse effects can be increased when Tositumomab is combined with Crotedumab. |
| Alemtuzumab | The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Crotedumab. |
| Capromab pendetide | The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Crotedumab. |
| Efalizumab | The risk or severity of adverse effects can be increased when Efalizumab is combined with Crotedumab. |
| Antithymocyte immunoglobulin (rabbit) | The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Crotedumab. |
| Natalizumab | The risk or severity of adverse effects can be increased when Natalizumab is combined with Crotedumab. |
| Palivizumab | The risk or severity of adverse effects can be increased when Palivizumab is combined with Crotedumab. |
| Daclizumab | The risk or severity of adverse effects can be increased when Daclizumab is combined with Crotedumab. |
| Bevacizumab | The risk or severity of adverse effects can be increased when Bevacizumab is combined with Crotedumab. |
| Technetium Tc-99m arcitumomab | The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Crotedumab. |
| Eculizumab | The risk or severity of adverse effects can be increased when Eculizumab is combined with Crotedumab. |
| Panitumumab | The risk or severity of adverse effects can be increased when Panitumumab is combined with Crotedumab. |
| Ranibizumab | The risk or severity of adverse effects can be increased when Ranibizumab is combined with Crotedumab. |
| Galiximab | The risk or severity of adverse effects can be increased when Galiximab is combined with Crotedumab. |
| Pexelizumab | The risk or severity of adverse effects can be increased when Pexelizumab is combined with Crotedumab. |
| Afelimomab | The risk or severity of adverse effects can be increased when Afelimomab is combined with Crotedumab. |
| Epratuzumab | The risk or severity of adverse effects can be increased when Epratuzumab is combined with Crotedumab. |
| Bectumomab | The risk or severity of adverse effects can be increased when Bectumomab is combined with Crotedumab. |
| Oregovomab | The risk or severity of adverse effects can be increased when Oregovomab is combined with Crotedumab. |
| IGN311 | The risk or severity of adverse effects can be increased when IGN311 is combined with Crotedumab. |
| Adecatumumab | The risk or severity of adverse effects can be increased when Adecatumumab is combined with Crotedumab. |
| Labetuzumab | The risk or severity of adverse effects can be increased when Labetuzumab is combined with Crotedumab. |
| Matuzumab | The risk or severity of adverse effects can be increased when Matuzumab is combined with Crotedumab. |
| Fontolizumab | The risk or severity of adverse effects can be increased when Fontolizumab is combined with Crotedumab. |
| Bavituximab | The risk or severity of adverse effects can be increased when Bavituximab is combined with Crotedumab. |
| CR002 | The risk or severity of adverse effects can be increased when CR002 is combined with Crotedumab. |
| Rozrolimupab | The risk or severity of adverse effects can be increased when Rozrolimupab is combined with Crotedumab. |
| Girentuximab | The risk or severity of adverse effects can be increased when Girentuximab is combined with Crotedumab. |
| Obiltoxaximab | The risk or severity of adverse effects can be increased when Obiltoxaximab is combined with Crotedumab. |
| XTL-001 | The risk or severity of adverse effects can be increased when XTL-001 is combined with Crotedumab. |
| NAV 1800 | The risk or severity of adverse effects can be increased when NAV 1800 is combined with Crotedumab. |
| Briakinumab | The risk or severity of adverse effects can be increased when Briakinumab is combined with Crotedumab. |
| Otelixizumab | The risk or severity of adverse effects can be increased when Otelixizumab is combined with Crotedumab. |
| AMG 108 | The risk or severity of adverse effects can be increased when AMG 108 is combined with Crotedumab. |
| Iratumumab | The risk or severity of adverse effects can be increased when Iratumumab is combined with Crotedumab. |
| Enokizumab | The risk or severity of adverse effects can be increased when Enokizumab is combined with Crotedumab. |
| Ramucirumab | The risk or severity of adverse effects can be increased when Ramucirumab is combined with Crotedumab. |
| Farletuzumab | The risk or severity of adverse effects can be increased when Farletuzumab is combined with Crotedumab. |
| Veltuzumab | The risk or severity of adverse effects can be increased when Veltuzumab is combined with Crotedumab. |
| Ustekinumab | The risk or severity of adverse effects can be increased when Ustekinumab is combined with Crotedumab. |
| Trastuzumab emtansine | The risk or severity of adverse effects can be increased when Trastuzumab emtansine is combined with Crotedumab. |
| PRO-542 | The risk or severity of adverse effects can be increased when PRO-542 is combined with Crotedumab. |
| TNX-901 | The risk or severity of adverse effects can be increased when TNX-901 is combined with Crotedumab. |
| Inotuzumab ozogamicin | The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Crotedumab. |
| RI 624 | The risk or severity of adverse effects can be increased when RI 624 is combined with Crotedumab. |
| Stamulumab | The risk or severity of adverse effects can be increased when MYO-029 is combined with Crotedumab. |
| CT-011 | The risk or severity of adverse effects can be increased when CT-011 is combined with Crotedumab. |
| Leronlimab | The risk or severity of adverse effects can be increased when Leronlimab is combined with Crotedumab. |
| Glembatumumab vedotin | The risk or severity of adverse effects can be increased when Glembatumumab vedotin is combined with Crotedumab. |
| Olaratumab | The risk or severity of adverse effects can be increased when Olaratumab is combined with Crotedumab. |
| IPH 2101 | The risk or severity of adverse effects can be increased when IPH 2101 is combined with Crotedumab. |
| TB-402 | The risk or severity of adverse effects can be increased when TB-402 is combined with Crotedumab. |
| Caplacizumab | The risk or severity of adverse effects can be increased when Caplacizumab is combined with Crotedumab. |
| IMC-1C11 | The risk or severity of adverse effects can be increased when IMC-1C11 is combined with Crotedumab. |
| Eldelumab | The risk or severity of adverse effects can be increased when Eldelumab is combined with Crotedumab. |
| Lumiliximab | The risk or severity of adverse effects can be increased when Lumiliximab is combined with Crotedumab. |